ACCOUNTS - Final Accounts

Registered number: 05644329

INQPHARM CONSUMER HEALTH LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

INQPHARM CONSUMER HEALTH LIMITED

REGISTERED NUMBER: 05644329

STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2024

		2024		2023
Note		£		£

Fixed assets
Intangible assets	4		4,142		9,231
Investments	5		22,643		22,643
			26,785		31,874
Current assets
Stocks		3,532		141,151
Debtors: amounts falling due within one year	6	791,208		580,714
Cash at bank and in hand		80,419		163,578
		875,159		885,443
Creditors: amounts falling due within one year	7	(1,472,072)		(1,421,416)
Net current liabilities			(596,913)		(535,973)
Total assets less current liabilities			(570,128)		(504,099)

Net liabilities			(570,128)		(504,099)

Capital and reserves
Called up share capital	8	400,000	400,000
Profit and loss account		(970,128)	(904,099)
		(570,128)	(504,099)

Page 1

INQPHARM CONSUMER HEALTH LIMITED

REGISTERED NUMBER: 05644329

STATEMENT OF FINANCIAL POSITION (CONTINUED)

AS AT 31 DECEMBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 23 September 2025.

T C Hafner

Director

The notes on pages 3 to 8 form part of these financial statements.

Page 2

INQPHARM CONSUMER HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1.Accounting policies

1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The Company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is a parent qualifies as a small group. The financial statements present information about the Company as an individual entity and not about its group.

The following principal accounting policies have been applied:

1.2

Going concern

At 31 December 2024 the Company had net liabilities of £570,128. The parent undertaking and ultimate shareholders have confirmed their willingness to support the Company for the forseeable future.

Page 3

INQPHARM CONSUMER HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1.Accounting policies (continued)

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

∙the Company has transferred the significant risks and rewards of ownership to the buyer;

∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;

∙the amount of revenue can be measured reliably;

∙it is probable that the Company will receive the consideration due under the transaction; and

∙the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

∙the amount of revenue can be measured reliably;

∙it is probable that the Company will receive the consideration due under the contract;

∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and

∙the costs incurred and the costs to complete the contract can be measured reliably.

1.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

1.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

1.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

INQPHARM CONSUMER HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1.Accounting policies (continued)

1.6

Foreign currency translation

Functional and presentation currency

The Company's functional currency is EUR. This differs from the presentational currency which is GBP. The reason for the difference is that the company operates in Europe. Monetary amounts in these financial statements are rounded to the nearest £.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

1.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

1.8

Interest income

Interest income is recognised in profit or loss using the effective interest method.

1.9

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

1.10

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Page 5

INQPHARM CONSUMER HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1.Accounting policies (continued)

1.11

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.	General information

InQpharm Consumer Health Limited is a private company, limited by shares and incorporated in England.
Its registered number is: 05644329
Its Registered Office is:
Invision House
Wilbury Way
Hitchin
Hertfordshire
SG4 0TY

Employees

The Company has no employees other than the directors, who did not receive any remuneration (2023 - £NIL).

Page 6

INQPHARM CONSUMER HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

4.	Intangible assets

		Patents
		£
	Cost
	At 1 January 2024	9,231
	At 31 December 2024	9,231
	Amortisation
	Charge for the year on owned assets	5,089
	At 31 December 2024	5,089
	Net book value
	At 31 December 2024	4,142
	At 31 December 2023	9,231

5.	Fixed asset investments

		Investments in subsidiary companies
		£
	Cost or valuation
	At 1 January 2024	22,643
	At 31 December 2024	22,643

Page 7

INQPHARM CONSUMER HEALTH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

Debtors

					2024	2023
					£	£


Trade debtors	241,506	110,033
Amounts owed by connected companies	503,923	426,123
Other debtors	41,612	14,630
Prepayments and accrued income	4,167	29,928
	791,208	580,714

7.	Creditors: Amounts falling due within one year
		2024	2023
		£	£

Payments received on account	316,516	-
Trade creditors	133,226	23,170
Amounts owed to connected companies	820,424	940,822
Other creditors	-	316,516
Accruals and deferred income	201,906	140,908
	1,472,072	1,421,416

8.	Share capital
		2024	2023
		£	£

Allotted, called up and fully paid

400,000 (2023 - 400,000) Ordinary shares of £1.00 each	400,000	400,000

9.	Controlling party

The immediate parent undertaking is Zaluvida Ventures Limited, their registered office is located at Invision House, Wilbury Way, Hitchin, Hertfordshire, SG4 0TY.
The ultimate parent undertaking is CTL Familienstiftung, a Trust registered in Liechtenstein, their registered office is Feldkircher Strasse 15, 9494 Schaan, Liechtenstein.
The trustee is Dr H Schwärzler.

Page 8